A Costly Settlement Weighs on Bayer's Financial Outlook

Bayer faces a €5B litigation hit in 2024, revising 2026 free cash flow to negative after a major glyphosate settlement. Debt to hit €33B as share price falls.

Bayer's financial planning has been thrown into disarray following preliminary approval of a multi-billion dollar settlement in the U.S. state of Missouri. The agreement, tied to the legacy Monsanto glyphosate litigation, represents a severe financial blow that threatens to overshadow operational progress within the current fiscal year.

The core of the settlement involves a sum of approximately $7.25 billion. This court-approved class action resolution in Missouri stands as one of the largest single provisions in the protracted legal battle surrounding the Roundup weedkiller. The impact on the company's balance sheet is profound. Management has been forced to issue a drastic revision to its 2026 free cash flow forecast, which is now expected to be deeply negative. Executives anticipate an outflow of between €1.5 and €2.5 billion, driven largely by an estimated €5 billion in litigation-related payments due this year alone. Meanwhile, adjusted EBITDA is projected to land in a range of €9.1 to €9.6 billion.

These sobering developments have left a clear mark on the company's share price. The stock has declined 9.50% over the past month, closing Friday's session at €37.78. While the shares continue to trade above the 200-day moving average of €33.24, the positive momentum seen in prior months has evaporated. Operational countermeasures, including new pharmaceutical products like Kerendia and efficiency programs in the agricultural division, are being implemented. However, these efforts are being overshadowed by persistently high energy costs and the overwhelming burden of historical legal liabilities.

Mounting Debt and a Pivotal June Date

Financial pressure on the Leverkusen-based group shows no sign of abating. By year-end, Bayer calculates its net financial debt will reach €32 to €33 billion. Investors are now looking ahead to a critical date in June 2026, when the U.S. Supreme Court is scheduled to rule on the so-called "Durnell" case. This pending decision from the nation's highest court possesses the potential to fundamentally redefine future glyphosate liability risks, effectively setting the parameters for the company's financial flexibility in the years to come.